Glenn P. Muir's most recent trade in Cytek BioSciences Inc was a trade of 55,555 Restricted Stock Units done . Disclosure was reported to the exchange on June 10, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Cytek BioSciences Inc | Glenn P. Muir | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2026 | 55,555 | 55,555 | - | - | Restricted Stock Units | |
| Cytek BioSciences Inc | Glenn P. Muir | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2026 | 29,835 | 29,835 | - | - | Director Stock Option (right to buy) | |
| Neuronetics Inc | Glenn P. Muir | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 May 2026 | 30,000 | 401,816 (2%) | 0% | 0 | Common Stock | |
| Repligen Corp | Glenn P. Muir | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2026 | 2,239 | 2,239 | - | - | Stock Option (Right to Buy) | |
| Repligen Corp | Glenn P. Muir | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2026 | 995 | 40,051 (0%) | 0% | 0 | Common Stock | |
| Repligen Corp | Glenn P. Muir | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 May 2026 | 2,434 | 2,434 | - | - | Stock Option (Right to Buy) | |
| Repligen Corp | Glenn P. Muir | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 38.76 per share. | 07 May 2026 | 2,434 | 39,056 (0%) | 0% | 38.8 | 94,342 | Common Stock |
| Repligen Corp | Glenn P. Muir | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Dec 2025 | 3,366 | 3,366 | - | - | Stock Option (Right to Buy) | |
| Repligen Corp | Glenn P. Muir | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 26.12 per share. | 16 Dec 2025 | 3,366 | 36,622 (0%) | 0% | 26.1 | 87,920 | Common Stock |
| Neuronetics Inc | Glenn P. Muir | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Oct 2025 | 7,554 | 371,816 (1%) | 0% | 0 | Common Stock | |
| Neuronetics Inc | Glenn P. Muir | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 May 2025 | 30,000 | 364,262 (1%) | 0% | - | Common Stock | |
| Repligen Corp | Glenn P. Muir | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2025 | 1,800 | 1,800 | - | - | Stock Option (Right to Buy) | |
| Repligen Corp | Glenn P. Muir | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2025 | 973 | 33,256 (0%) | 0% | 0 | Common Stock | |
| Neuronetics Inc | Glenn P. Muir | Director | Other type of transaction at price $ 2.25 per share. | 07 Feb 2025 | 44,444 | 334,262 (1%) | 0% | 2.3 | 99,999 | Common Stock |
| Repligen Corp | Glenn P. Muir | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 36.29 per share. | 19 Nov 2024 | 19,000 | 32,283 (0%) | 0% | 36.3 | 689,510 | Common Stock |
| Repligen Corp | Glenn P. Muir | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Nov 2024 | 19,000 | 0 | - | - | Stock Option (Right to Buy) | |
| G1 Therapeutics Inc | Glenn P. Muir | Director | 18 Sep 2024 | 185,358 | 0 (0%) | 0% | - | Common Stock | ||
| G1 Therapeutics Inc | Glenn P. Muir | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 18 Sep 2024 | 50,000 | 0 | - | - | Stock Option (right to buy) | |
| G1 Therapeutics Inc | Glenn P. Muir | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 18 Sep 2024 | 30,000 | 0 | - | - | Stock Option (right to buy) | |
| G1 Therapeutics Inc | Glenn P. Muir | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 18 Sep 2024 | 30,000 | 0 | - | - | Stock Option (right to buy) | |
| G1 Therapeutics Inc | Glenn P. Muir | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 18 Sep 2024 | 30,000 | 0 | - | - | Stock Option (right to buy) | |
| G1 Therapeutics Inc | Glenn P. Muir | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 18 Sep 2024 | 20,000 | 185,358 (0%) | 0% | - | Common Stock | |
| Neuronetics Inc | Glenn P. Muir | Director | Purchase of securities on an exchange or from another person at price $ 0.80 per share. | 05 Sep 2024 | 25,000 | 289,818 (1%) | 0% | 0.8 | 20,000 | Common Stock |
| Neuronetics Inc | Glenn P. Muir | Director | Purchase of securities on an exchange or from another person at price $ 0.85 per share. | 28 Aug 2024 | 12,776 | 252,594 (1%) | 0% | 0.9 | 10,860 | Common Stock |
| Neuronetics Inc | Glenn P. Muir | Director | Purchase of securities on an exchange or from another person at price $ 0.85 per share. | 28 Aug 2024 | 12,224 | 264,818 (1%) | 0% | 0.8 | 10,390 | Common Stock |
| Neuronetics Inc | Glenn P. Muir | Director | Purchase of securities on an exchange or from another person at price $ 1.00 per share. | 20 Aug 2024 | 25,000 | 239,818 (1%) | 0% | 1 | 25,000 | Common Stock |
| Neuronetics Inc | Glenn P. Muir | Director | Purchase of securities on an exchange or from another person at price $ 0.75 per share. | 14 Aug 2024 | 25,171 | 214,818 (1%) | 0% | 0.7 | 18,878 | Common Stock |
| Repligen Corp | Glenn P. Muir | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Aug 2024 | 5,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Repligen Corp | Glenn P. Muir | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 36.29 per share. | 01 Aug 2024 | 5,000 | 13,283 (0%) | 0% | 36.3 | 181,450 | Common Stock |
| G1 Therapeutics Inc | Glenn P. Muir | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2024 | 30,000 | 30,000 | - | - | Stock Options (Right to Buy) | |
| G1 Therapeutics Inc | Glenn P. Muir | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2024 | 10,000 | 205,358 (0%) | 0% | 0 | Common Stock | |
| Neuronetics Inc | Glenn P. Muir | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 May 2024 | 25,000 | 189,647 (1%) | 0% | - | Common Stock | |
| Repligen Corp | Glenn P. Muir | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2024 | 1,376 | 1,376 | - | - | Stock Option (Right to Buy) | |
| Repligen Corp | Glenn P. Muir | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2024 | 701 | 8,283 (0%) | 0% | 0 | Common Stock | |
| G1 Therapeutics Inc | Glenn P. Muir | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2023 | 30,000 | 30,000 | - | - | Stock Options (Right to Buy) | |
| G1 Therapeutics Inc | Glenn P. Muir | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2023 | 10,000 | 195,358 (0%) | 0% | 0 | Common Stock | |
| Neuronetics Inc | Glenn P. Muir | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2023 | 36,364 | 164,647 (0%) | 0% | - | Common Stock | |
| Repligen Corp | Glenn P. Muir | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2023 | 1,487 | 1,487 | - | - | Stock Option (Right to Buy) | |
| Repligen Corp | Glenn P. Muir | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2023 | 686 | 7,582 (0%) | 0% | 0 | Common Stock | |
| G1 Therapeutics Inc | Glenn P. Muir | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2022 | 30,000 | 30,000 | - | - | Stock Options (Right to Buy) | |
| G1 Therapeutics Inc | Glenn P. Muir | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2022 | 10,000 | 185,358 (0%) | 0% | 0 | Common Stock | |
| Neuronetics Inc | Glenn P. Muir | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2022 | 38,910 | 128,271 (0%) | 0% | - | Common Stock | |
| Repligen Corp | Glenn P. Muir | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2022 | 1,298 | 1,298 | - | - | Stock Option (Right to Buy) | |
| Repligen Corp | Glenn P. Muir | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2022 | 534 | 6,896 (0%) | 0% | 0 | Common Stock |